Brian Miller, MD
Psychiatry · la Mesa, CANPI 1861411381
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $114,778 of the $146,465 with a category attached, or 78.4%. Alkermes, Inc. accounts for 87.9% of it on its own, with 16 other manufacturers making up the rest. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $491.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$129K
- Johnson & Johnson$5K
- E.r. Squibb & Sons, L.L.C.$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Otsuka America Pharmaceutical, Inc.$3K
- Neurocrine Biosciences, Inc.$421
- plus $2K from 11 others
Across 1 payment — averaging $512.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$513
What the payments were for
- Consulting fees$15,44111%
- Speaking & faculty fees$114,77878%
- Travel & lodging$6,6105%
- Food & beverage$9,6107%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 167 | $128,716 |
| Johnson & Johnson | 24 | $4,988 |
| E.r. Squibb & Sons, L.L.C. | 18 | $4,386 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $3,148 |
| Otsuka America Pharmaceutical, Inc. | 18 | $3,143 |
| Neurocrine Biosciences, Inc. | 12 | $421 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 9 | $371 |
| Axsome Therapeutics, Inc. | 5 | $279 |
| Vanda Pharmaceuticals Inc. | 12 | $279 |
| Livanova USA, Inc. | 3 | $186 |
| H2-pharma, LLC | 1 | $150 |
| Teva Pharmaceuticals USA, Inc. | 6 | $129 |
| Lundbeck LLC | 5 | $95 |
| GSK | 3 | $54 |
| Indivior Inc. | 2 | $53 |
| Bioxcel Therapeutics, Inc. | 1 | $50 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$299,805
- ARISTADA$203,331
- ARISTADA INITIO$50,628
- SPRAVATO$4,751
- COBENFY$4,035
- CAPLYTA$3,000
- REXULTI$2,457
- ABILIFY MYCITE$351
- INGREZZA$144
- Auvelity$112
- ABILIFY ASIMTUFII$111
- ABILIFY MAINTENA$111
How this compares
$146,465 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 77 | $281,257 |
| SpravatoEsketamine Hcl | 36 | $212,386 |
| AristadaAripiprazole Lauroxil | 49 | $167,973 |
| FanaptIloperidone | 44 | $167,296 |
| LybalviOlanzapine/Samidorphan Malate | 58 | $97,877 |
| UzedyRisperidone | 20 | $59,347 |
| Chlorpromazine Hcl | 59 | $41,227 |
| Clozapine | 479 | $35,398 |
| Lurasidone Hcl | 151 | $35,349 |
| Olanzapine OdtOlanzapine | 97 | $17,315 |
| Divalproex Sodium | 177 | $16,915 |
| Olanzapine | 363 | $15,536 |
| Paliperidone ErPaliperidone | 63 | $12,893 |
| VraylarCariprazine Hcl | 18 | $12,413 |
| Haloperidol | 133 | $9,790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Spravato | $4,988 | $493,642113 claims |
| Alkermes, Inc.Aristada, Lybalvi | $128,716 | $265,851107 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $279 | $167,29644 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $129 | $59,34720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in la Mesa
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.